Document Migration


  • There may be as many as 8,000 rare diseases, affecting between 6% and 8% of the worldwide population in total. It is estimated there are about 30 million affected people in the EU and in North America, while over 45 million people may be suffering from a rare condition in Asia, with 10 million people in China alone.

  • Project Farma has tremendous experience in providing business and manufacturing strategy to early-stage startups, established life science companies, leading medical institutions and CROs/CMOs. The team can not only help define and develop the strategy for our partners but also execute the strategy with confidence.

  • Next-generation fluorescent imaging solution for the assurance of monoclonality and automated confluence across diverse cell types

    Demonstrating that cell lines are monoclonal – or that a gene was edited as expected – can be a time-consuming and highly-subjective process when relying on conventional technologies. The CloneSelect® Imager and CloneSelect® Imager FL are a high-throughput automated solutions for imaging and analyzing mammalian cells. Tracking the formation of a colony from a single cell is effortless as barcoded plates are tracked over time. Automated acquisition and analysis provides accurate, objective, and consistent results.

  • LMD 6 Laser Microdissection Microscope

    Dissection Perfection

    Laser Microdissection (LMD, also known as Laser Capture Microdissection or LCM) enables users to isolate specific single cells or entire areas of tissue. Powered by a unique laser design and dynamic software, Leica LMD systems allow users to easily isolate Regions of Interest (ROI) from entire areas of tissue down to single cells or even subcellular structures such as chromosomes.

    LMD is typically used in genomics (DNA), transcriptomics (mRNA, miRNA), proteomics, metabolomics, and even next generation sequencing (NGS). Researchers in neurology, cancer research, plant analysis, forensics or climate research rely on this method. Furthermore, LMD is a perfect tool for live cell culture (LCC), for cloning and re-cultivation, manipulation or downstream analysis.

    We move the laser, not the sample. And we use gravity for collection. That is why our LMD systems provide you with perfectly cut, contamination-free, analysis-ready dissectates.

  • Particle size reduction is a key process in laboratories and small scale manufacturing, right through to full size production.


  • The Workforce Productivity Service Opportunity For MSPs

    The future of work is rapidly evolving. In the last twelve months, the world has witnessed a seismic shift in the managed services landscape. The hybrid and remote working movement has spurred many companies to adopt flexible operations to support distributed teams, while facing unpredictable economic conditions. As a result, companies large and small are struggling to understand, manage, and optimize worker productivity.

  • Clinical Supply Optimization: Process Improvement Accelerates Trials

    A biopharmaceutical sponsor required the study start-up phase to be reduced to 91 days, involving comparator sourcing and blinding, kitting, packaging, labeling, and distribution to the sites.

  • Inova Health System Uses Advarra eReg Workflows And Integrations To Improve Regulatory Efficiency

    Maintaining efficient, effective regulatory management processes can be a significant challenge. At Inova Health System, the research team improved regulatory efficiency by 20% without the need for extra regulatory staff by adopting Advarra’s eRegulatory Management System.

  • Accelerating Results For Healthcare Brands Through Advocacy, Materials Science Expertise And Integrated Packaging Capabilities

    Any change to packaging design for an approved pharmaceutical product is a time consuming, detail-orientated effort, even with small brand-driven changes––so when governments update packaging regulations on a larger scale, a company’s entire product line could be impacted, creating change management projects for sometimes hundreds of items. When Health Canada introduced amendments to the existing Food and Drug Regulations for non-prescription, over-the-counter (OTC) drug products in 2014, pharmaceutical organizations selling products in the Canadian marketplace knew they had a significant challenge to overcome

  • Scaling Service Operations Amidst Disruption

    Our Services Use Cases present summary and analysis of a situational market scenario experienced by one or more of Source Support Services’ customers. Specific customer names and details have been removed for privacy.

  • Touchless Service Guide

    At the outset of the COVID-19 pandemic, few companies were prepared for the impact. Only 12% of 1,500 respondents surveyed by Gartner in March 2020 believed their business was highly prepared for the new realities of COVID-19. During the height of the pandemic, shelter in place orders, travel bans, and facility-wide lockdowns made the provision of field service extremely difficult. According to a study published by TSIA in April 2020, nearly three quarters (78%) of Field Service Organizations (FSOs) had either eliminated or restricted onsite field service dispatches in response to Covid-19 restrictions. Almost half (47%) of the companies surveyed renegotiated their Service Level Agreements(SLAs) with customers.

  • The State Of Automation, AI, And Data In Life Sciences

    Companies need to speed up their current development cycle, yet there are automation gaps across the drug development lifecycle.

  • Removing The Barriers To eConsent Adoption

    eConsent technology has existed for nearly 20 years in various iterations. Read how sponsors have taken a cautious approach to using eConsent, piloting it on individual studies but refraining from incorporating it across all pipelines in clinical operations.

  • How To Save 9k Hours And Cut Deviations By 27%

    This pharma company transitioned off paper, slashing their deviation count and saving thousands in onsite hours. Learn how they were able to streamline business operations and free up resources.

  • Common Reasons For FDA Form 483 Observations And Warning Letters In Medical Device Environments

    By understanding the FDA’s updated approach to medical device regulation and the information provided in the inspection observations document, medical device companies can more easily identify and mitigate compliance issues.

  • Three Key Considerations For Colocation Providers

    The events of 2020 forced organizations to quickly figure out how to close the gaps in their business continuity plans. And now they recognize that maintaining operational resiliency and enabling innovation moving forward requires ongoing transformation.

  • Taking Biotherapeutic Candidates From Late Discovery To The Clinic

    Many initially promising biotherapeutic candidates fail due to lack of efficacy or safety, but there are candidates that fail due to stability, aggregation, and other issues related to cell line or process issues.